Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5283651 | 0.81 | — | — | |
| SCHEMBL5281237 | 0.77 | — | — | |
| SCHEMBL1598544 | 0.72 | — | — | |
| SCHEMBL5279864 | 0.72 | — | — | |
| SCHEMBL5278959 | 0.71 | — | — | |
| SCHEMBL5275933 | 0.71 | — | — | |
| SCHEMBL5279708 | 0.71 | — | — | |
| SCHEMBL5273493 | 0.70 | — | — | |
| SCHEMBL5277608 | 0.70 | HCAR3 (0.33) | — | |
| SCHEMBL5281997 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323960-A1 | FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-10-21 | — | — | US | disclosed |
| EP-3822272-A1 | FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020011254-A1 | FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR | 正大天晴药业集团股份有限公司 | 2020-01-16 | — | — | WO | disclosed |
| WO-2011050160-A1 | PHARMACEUTICALS, COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-7276567-B2 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-10-02 | — | — | US | disclosed |
| US-20050261449-A1 | Heterocyclic substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENT INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323960-A1 | FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR | PDE3B, PDE4A, PDE3A | COMT 1230/4885NR2F2 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.